Arcutis Biotherapeutics reported $143.9 million in net product revenue from ZORYVE in the third quarter of 2026 and raised its full-year 2026 sales guidance. Earnings were $0.06 per share, below the consensus estimate of $0.17 and unchanged from the same period a year earlier. The company’s stock price declined after the results were announced.
The company reported earnings of $0.06 per share, missing analyst estimates of $0.17, despite strong sales growth for its key product ZORYVE.
Read the full storyArcutis Biotherapeutics reported Q3 earnings of $0.06 per share, falling short of the $0.17 consensus estimate while matching its prior-year performance.
The biotech firm reported $143.9 million in net product revenue for Q3, leading management to revise its full-year sales guidance upward following strong market adoption.